Results 231 to 240 of about 23,209 (275)

Palladium-Catalyzed Synthesis, Acetylcholinesterase Inhibition, and Neuroprotective Activities of N-Aryl Galantamine Analogues.

Journal of Natural Products, 2023
A series of new N-aryl galantamine analogues (5a-5x) were designed and synthesized by modification of galantamine, using Pd-catalyzed Buchwald-Hartwig cross-coupling reaction in good to excellent yields.
Yang Zhang, Jin-bu Xu, Yao Xiao, W. Ji, Lian-hai Shan, Linxi Wan, Xian-Li Zhou, Yu Lei, Feng Gao   +8 more
semanticscholar   +1 more source

Galantamine nanoparticles outperform oral galantamine in an Alzheimer's rat model: pharmacokinetics and pharmacodynamics.

Nanomedicine, 2021
Aim: Galantamine is an acetylcholinesterase inhibitor frequently used in Alzheimer's disease management. Its cholinergic adverse effects and rapid elimination limit its therapeutic outcomes.
S. El-Ganainy, Mennatallah A. Gowayed, M. Agami, Passant Mohamed, Marwa Belal, R. Farid, A. Hanafy   +6 more
semanticscholar   +1 more source

Effects of New Galantamine Derivatives in a Scopolamine Model of Dementia in Mice

Journal of Alzheimer's Disease, 2021
Alzheimer’s disease (AD), a progressive neurodegenerative disorder characterized by memory loss and cognitive functions decline, is a leading cause for dementia and currently ranked as the sixth foremost cause of death.
M. Lazarova, L. Tancheva, A. Alexandrova, Elina Tsvetanova, A. Georgieva, M. Stefanova, D. Tsekova, L. Vezenkov, R. Kalfin, D. Uzunova, P. Petkova-Kirova   +10 more
semanticscholar   +1 more source

New Galantamine Derivatives with Inhibitory Effect on Acetylcholinesterase Activity

Journal of Alzheimer's Disease, 2021
Background: Inhibitors of acetylcholinesterase (AChE) are used to treat many disorders, among which are neurodegenerative upsets, like Alzheimer’s disease (AD).
M. Lazarova, D. Tsekova, L. Tancheva, Kiril T Kirilov, D. Uzunova, L. Vezenkov, Elina Tsvetanova, A. Alexandrova, A. Georgieva, Petja T Gavrilova, Stela T. Dragomanova, Maria G Papazova, Yordan S Handzhiyski, R. Kalfin   +13 more
semanticscholar   +1 more source

Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.

Cochrane Database of Systematic Reviews
BACKGROUND Dementia leads to progressive cognitive decline, and represents a significant health and societal burden. Its prevalence is growing, with Alzheimer's disease as the leading cause.
Amanda Wei-Yin Lim, Lon S. Schneider, Clement Loy   +2 more
semanticscholar   +1 more source

Accuracy of Labeling of Galantamine Generic Drugs and Dietary Supplements.

Journal of the American Medical Association (JAMA)
This study examines the accuracy of labeling for galantamine products formulated as both generic drugs and dietary supplements, as well as tests for contamination with microorganisms.
Pieter A Cohen, Bram Jacobs, Koenraad Van Hoorde, C. Vanhee   +3 more
semanticscholar   +1 more source

Functionalized Graphene Quantum Dots as an Eco-Friendly Fluorescent Probe for Galantamine Analysis: Greenness Evaluation With Application to Pharmacokinetics Monitoring.

Luminescence (Chichester, England Print)
In this study, the use of functionalized graphene quantum dots (GQDs) as a fluorescent probe has been investigated for the quantitative determination of galantamine, a choline esterase inhibitor used for the treatment of Alzheimer's disease.
Manal E. Alosaimi, Atiah H. Almalki, Maram H. Abduljabbar, Reem M. Alnemari, Saleh I. Alaqel, Ahmed Serag   +5 more
semanticscholar   +1 more source

A Comprehensive Analysis on Galantamine Based Hybrids for the Management of Alzheimer's Disease

Chemical Biology and Drug Design
Alzheimer's disease (AD) is a progressive chronic age‐related neurodegenerative brain disorder characterized by the loss of memory and other cognitive functions.
Y. P. Singh, Sonima Prasad, Harish Kumar
semanticscholar   +1 more source

Galantamine Extended Release

CNS Drugs, 2006
Galantamine inhibits acetylcholinesterase (AChE) to slow acetylcholine hydrolysis, and may also modulate presynaptic nicotinic receptor activation, thereby increasing neurotransmitter concentrations in the synaptic cleft.black triangle Once-daily galantamine extended release (ER) 24 mg and twice-daily galantamine immediate release (IR) 12 mg are ...
Dean M, Robinson, Greg L, Plosker
openaire   +2 more sources

“Plurol will not miss the boat”: A new manifesto of galantamine conveyance

Journal of Drug Delivery Science and Technology, 2022
Heba A. Gad, M. Mansour, H. Abbas, Rania T Malatani, M. A. Khattab, Enas M. Elmowafy   +5 more
semanticscholar   +1 more source